BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Redburn Atlantic

Analysts at Redburn Atlantic assumed coverage on shares of BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) in a research note issued on Monday, MarketBeat reports. The firm set a "buy" rating and a $50.00 price target on the stock. Redburn Atlantic's price target suggests a potential upside of 55.02% from the stock's current price.

Several other analysts have also commented on the company. Citigroup boosted their price target on BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Evercore ISI boosted their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an "outperform" rating in a research note on Monday, December 23rd. JPMorgan Chase & Co. increased their target price on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a research report on Monday, March 24th. HC Wainwright restated a "buy" rating and issued a $49.00 price target on shares of BridgeBio Pharma in a research report on Thursday, February 13th. Finally, Scotiabank upped their price objective on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Friday, February 21st. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat, BridgeBio Pharma presently has a consensus rating of "Moderate Buy" and an average price target of $52.64.

Remove Ads

BridgeBio Pharma Stock Down 5.3 %

BridgeBio Pharma stock traded down $1.82 on Monday, hitting $32.25. The company's stock had a trading volume of 1,522,243 shares, compared to its average volume of 2,206,337. The company has a fifty day moving average price of $34.13 and a 200-day moving average price of $29.46. The firm has a market cap of $6.13 billion, a P/E ratio of -11.40 and a beta of 1.08. BridgeBio Pharma has a one year low of $21.62 and a one year high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The company had revenue of $5.88 million for the quarter, compared to analysts' expectations of $4.04 million. Analysts anticipate that BridgeBio Pharma will post -3.67 EPS for the current year.

Insider Activity at BridgeBio Pharma

In other news, Director Andrea Ellis sold 30,000 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $34.05, for a total transaction of $1,021,500.00. Following the completion of the sale, the director now owns 12,000 shares in the company, valued at $408,600. The trade was a 71.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Neil Kumar sold 326,932 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the sale, the chief executive officer now directly owns 5,371,515 shares of the company's stock, valued at approximately $194,932,279.35. This trade represents a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,684,739 shares of company stock worth $326,958,651 over the last 90 days. Insiders own 24.66% of the company's stock.

Institutional Investors Weigh In On BridgeBio Pharma

A number of institutional investors have recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC boosted its holdings in BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after buying an additional 472 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in BridgeBio Pharma during the 4th quarter worth approximately $41,000. Sterling Capital Management LLC grew its holdings in BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock valued at $49,000 after purchasing an additional 1,514 shares during the period. GF Fund Management CO. LTD. bought a new stake in BridgeBio Pharma in the fourth quarter valued at approximately $109,000. Finally, Avanza Fonder AB bought a new stake in shares of BridgeBio Pharma in the 4th quarter valued at $181,000. 99.85% of the stock is owned by institutional investors and hedge funds.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.